Metabolic Syndrome and Neuroprotection

Melisa Etchegoyen, Mariana H. Nobile, Francisco Baez, Barbara Posesorski, Julian González, Néstor Lago, José Milei and Matilde Otero-Losada

Introduction: Over the years the prevalence of metabolic syndrome (MetS) has drastically increased in developing countries as a major byproduct of industrialization. Many factors, such as the consumption of high-calorie diets and a sedentary lifestyle, bolster the spread of this disorder. Undoubtedly, the massive and still increasing incidence of MetS places this epidemic as an important public health issue. Hereon we revisit another outlook of MetS beyond its classical association with cardiovascular disease (CVD) and Diabetes Mellitus Type 2 (DM2), for MetS also poses a risk factor for the nervous tissue and threatens neuronal function. First, we revise a few essential concepts of MetS pathophysiology. Second, we explore some neuroprotective approaches in MetS pertaining brain hypoxia. The articles chosen for this review range from the years 1989 until 2017; the selection criteria was based on those providing data and exploratory information on MetS as well as those that studied innovative therapeutic approaches.

Pathophysiology: The characteristically impaired metabolic pathways of MetS lead to hyperglycemia, insulin resistance (IR), inflammation, and hypoxia, all closely associated with an overall pro-oxidative status. Oxidative stress is well-known to cause the wreckage of cellular structures and tissue architecture. Alteration of the redox homeostasis and oxidative stress alter the macromolecular array of DNA, lipids, and proteins, in turn disrupting the biochemical pathways necessary for normal cell function.

Neuroprotection: Different neuroprotective strategies are discussed involving lifestyle changes, medication aimed to mitigate MetS cardinal symptoms, and treatments targeted toward reducing oxidative stress. It is well-known that the routine practice of physical exercise, aerobic activity in particular, and a complete and well-balanced nutrition are key factors to prevent MetS. Nevertheless, pharmacological control of MetS as a whole and pertaining hypertension, dyslipidemia, and endothelial injury contribute to neuronal health improvement.

Conclusion: The development of MetS has risen as a risk factor for neurological disorders. The therapeutic strategies include multidisciplinary approaches directed to address different pathological pathways all in concert.

Keywords: metabolic syndrome X, neuroprotection, hypoxia, brain, oxidative stress, antioxidants
INTRODUCTION

Definition
Metabolic syndrome (MetS) is a disorder characterized by a cluster of conditions that increases the risk of developing cardiovascular disease (CVD) and Type 2 Diabetes Mellitus (DM2) (International Diabetes Federation, 2006). Currently, there are still controversies among the different Health Organizations on the selection criteria for this syndrome. The most accepted diagnostic tool is the global consensus described by the International Diabetes Federation (IDF) (International Diabetes Federation, 2006) that entails the presence of:

- Central obesity (based on waist circumference): ≥80 cm for women and ≥90 cm for men from the Hispanic background (values vary with ethnicity).
- Plus two or more of the following parameters:
  1. **Hypertriglyceridemia**: ≥150 mg/dL, or under treatment for this lipid abnormality.
  2. **HDL-cholesterolemia below recommendations**: <40 mg/dL in men and <50 mg/dL in women, or history of specific treatment for this lipid abnormality.
  3. **Hypertension**: SBP ≥130 mmHg and/or DBP ≥85 mmHg over 24 h.
  4. **Fasting Hyperglycemia**: ≥100 mg/dL, hyperinsulinemia, or DM2.

Metabolic syndrome (MetS) has been associated with hepatic steatosis, respiratory illness, osteoarticular disease, and cancer (Siegel and Zhu, 2009). The main mechanism implicated in the pathogenesis of MetS is the resistance to insulin (IR), namely the insufficient response to physiological insulin levels (Eckel, 2005). Other aspects that can shape MetS pathology are environmental stressors, mostly chemical, infections, lifestyle (sedentary habits, smoking, and nutritional factors), genetic predisposition, and other chronic diseases. These characteristics have one common denominator which is the generalized pro-oxidative status, in turn favoring free radical generation and resulting in oxidative stress (Roberts and Sindhu, 2009). The specific metabolic pathways typically affected by the development of MetS are discussed in more detail later in this work.

Epidemiology
Metabolic syndrome (MetS) affects nearly 30% of the world population, associated with a 2–3-fold increase in morbidity and mortality compared with healthy people (Engin, 2017). In regard to the general statistics of MetS, an important item to highlight is the lack of unanimity on the diagnosis of this syndrome, specifically derived from the regional variation of the cut-off values for waist circumference linked to ethnicity (Borch-Johnsen, 2013). Therefore, the percentage calculated on a worldwide scale is only approximated and should be adjusted based on the prevalent ethnicity in a national scope.

Despite any criteria discrepancy, the need to reduce the prevalence of this disorder on a global scale becomes relevant. Not only does the presence of MetS reduce life expectancy and quality of life, but it also causes a financial burden derived from high health costs (Rask-Madsen and Kahn, 2012). For this reason, the World Health Organization (WHO) has as a priority to lower the worldwide prevalence of non-communicable diseases like CVD, DM2, and cancer, globally accounting for 63% of overall deaths. One example of this intended approach is the taxing of sweetened beverages.\(^1\)

As aforementioned, MetS increases mortality and morbidity and is associated with accelerated aging (Rask-Madsen and Kahn, 2012). The aging process per se increases an individual’s susceptibility to developing CVD or DM2. Interestingly, some reports substantiate how MetS even in the absence of CVD or DM2 also renders higher morbimortality (Borch-Johnsen, 2013).

The relevance of MetS in the modern industrialized society is undeniable. Its staggering global prevalence and concomitantly diminished quality of life rank this disorder as a major public health concern.

Effects of Metabolic Syndrome on the Nervous System
Over the years, the importance of MetS pertaining cardiovascular risk and progression to DM2 has been carefully studied and extensively divulged, for CVD is the leading cause of death worldwide.\(^2\) However, research has been scarce with regard to the effects of MetS on nervous tissue. In the recent years, the ever-growing evidence suggests a correlation between Alzheimer’s disease (AD) and other cognitive impairments, and MetS. These results suggest that this syndrome does not only act as a risk factor for CVD and DM2 but also contributes to the progression toward AD (Kim and Feldman, 2015).

The nervous tissue has two vastly different cell populations: neuronal and glial cells. Neurons are highly specialized cells that propagate electrical stimulus in order to accomplish synaptic transmission, while the glia (composed mainly by astrocytes, oligodendrocytes, and microglia) is responsible for maintaining the homeostasis in nervous tissue. The brain depends upon glucose as its main source of energy, and a tight regulation of glucose metabolism and ATP reserves are critical for brain physiology (Mergenthaler et al., 2013; Brusco et al., 2014).

The aim of this review is:

1. First, to revise the pathophysiology of MetS and the consequences of the intrinsically altered metabolism in the nervous tissue.
2. To propose and explore different therapeutic approaches aimed at reducing the compromised neuronal function and neurodegenerative damage in MetS.

PATHOPHYSIOLOGY
Overview
It is imperative to acknowledge that MetS develops in susceptible individuals bearing genetic factors and engaging in certain epigenetic unhealthy habits like a sedentary lifestyle, excessive

---

\(^1\)WHO Mid-term Programmatic and Financial Report for 2016–2017 including audited financial statements for 2016 (WHA 70/40) (http://www.who.int/about/finances-accountability/reports/en/).

\(^2\)World Health Organization. The top 10 causes of death (Fact sheet) Updated January 2017 http://www.who.int/mediacentre/factsheets/fs310/en/.
consumption of high energy foods and drinks, smoking, and many others. This complex disorder is characterized by a sustained positive energy balance, which progressively breeds a mild inflammatory environment due to the activation of abnormal metabolic pathways (Kaur, 2014). Pivotal mechanisms implied in MetS were described in this review: hyperglycemia, insulin resistance (IR), inflammation and oxidative stress.

Patients with long-term MetS may be prone to develop diabetic encephalopathy due to the diabetogenic milieu, entailing moderate cognitive deficits, and both neurophysiological and structural changes in the brain (Bissels et al., 2002). Passos et al. demonstrated that the senescent cells had higher reactive oxygen species (ROS) concentration, dysfunctional mitochondria, more DNA double-strand breaks and shorter telomeres. It was also shown that mitochondrial ROS enhanced telomere-dependent senescence (Passos et al., 2007). Likewise, some authors showed the link between telomere length and metabolic disease suggesting increased cellular turnover and therefore accelerated cell aging (Bonomini et al., 2011; Kong et al., 2013). The increasing abdominal adiposity typical of the MetS is accompanied by accelerated telomere attrition (Révézé et al., 2015).

**Hyperglycemia**

It is well-known that a high concentration of blood glucose triggers diverse metabolic pathways. The most evident is the tricarboxylic acid (TCA) cycle, due to an abundant amount of substrate that in turn feeds the succeeding electron transport chain (ETC). This energy surplus creates an imbalance of partially reduced oxygen species favoring oxidant over antioxidant compounds and resulting in oxidative stress (Kawahito et al., 2009).

Another thoroughly described mechanism is the network of glycation reactions bringing forth oxidative stress alongside glucose toxicity (Kaneto et al., 1996). Advanced glycation end-products (AGEs) are formed as a result of these non-enzymatic reactions and promote inflammation by interacting with the receptor of AGEs (RAGE) in cells of the immune system (Gkogkolou and Böhm, 2012). The activation of the RAGE triggers abundant intracellular signaling pathways including kinases (e.g., MAP kinases, PI3 kinase), transcription factors as the nuclear factor-κB (NFκB), and the activator protein-1. This signaling cascade activates the further expression of cytokines, chemokines, enzymes, and growth factors resulting in an overall proinflammatory environment which leads to oxidative stress (Medzhito and Horng, 2009).

Moreover, hyperglycemia reduces antioxidant levels and increases the production of free radicals. The enzymes superoxide dismutase (SOD) and catalase or glutathione peroxidase involved in the antioxidant defense are down-regulated in the diabetic brain (Suresh Kumar and Menon, 1993; Makar et al., 1995; Miranda et al., 2007; Alvarez-Nölting et al., 2012). The possible source of oxidative stress in brain injury, however, also includes auto-oxidation of glucose, lipid peroxidation, and decreased tissue concentrations of low molecular weight antioxidants like reduced glutathione (GSH) (Reagan et al., 2000; Grillo et al., 2003; Ulusu et al., 2003; Muriach et al., 2006). This alteration of reduced glutathione levels may be related to an increased activity of the polyclonal pathway as this leads to a depletion of the NADPH required for enzymatic reduction of the oxidized glutathione (Preet et al., 2005).

Overall, hyperglycemia creates a pro-oxidative environment in live tissue involving various mechanisms. This condition causes a detrimental effect on various cells and tissues, especially those more vulnerable due to an insufficient antioxidant defense like the pancreatic β-cells (Kaneto et al., 1999).

**Insulin Resistance**

Insulin is well-known for its role in the regulation of glucose metabolism in the body. However, insulin has other roles in the central nervous system (CNS) pertaining cognitive processes, memory and synaptic plasticity (Zhao and Alkon, 2001). Accordingly, either the deficiency of insulin or hyperinsulinemia characteristic of type 1 or type 2 diabetes mellitus respectively could be associated with degenerative events in the brain (Xu et al., 2004).

Recent studies have suggested that the nervous system is also capable of developing resistance to insulin. This is possible even though neurons are not dependent on insulin, they bear insulin receptors and are insulin-responsive (Belfiore et al., 2009). Insulin receptors are expressed in brain areas as the olfactory bulb, cerebral cortex, hippocampus, hypothalamus and amygdala. Resistance to insulin in sensory neurons affects the cellular response to growth factors, leading to neurodegeneration, and neuropathy over time. In regard to mitochondrial metabolism, insulin regulates the PI3K/Akt (phosphatidylinositol 3-kinase-serine/threonine-specific Protein Kinase B) intracellular transduction signaling pathway (Stiles, 2009; Cheng et al., 2010) which promotes survival and growth in response to extracellular signals. This, in turn, affects neuronal mitochondria, resulting in increased oxidative stress (Fisher-Wellman and Neufer, 2012).

In addition, evidence has convincingly reported the involvement of the mechanistic mammalian target of rapamycin (mTOR) in cellular senescence. This pathway is activated by an insulin dependent signal. The mTOR modulates cell growth and cellular metabolism in response to growth factors, nutrients, and cellular energy conditions. The loss of mTOR signaling disrupts multiple responses in glucose metabolism, energy production, mitochondrial function, and cell growth (Blagosklonny, 2013).

**Inflammation**

Inflammation is a biologically essential process which stands as a common denominator in various pathological circumstances. The inflammatory reaction is triggered in response to tissue damage in an attempt to restore tissue homeostasis via repairing mechanisms. In physiological conditions, the inflammatory reaction is controlled and self-limited. However, when the fine orchestrated regulation of these mechanisms is disrupted, the uncontrolled inflammatory response usually ends in collateral damage (Goldszmid and Trinchieri, 2012).

The amazingly complex immune system mediates the response to unknown stimuli. When the inflammatory response is unable to restore homeostasis, systemic, and cellular stress
persists and physiological abnormalities develop (Okin and Medzhitov, 2012). Diabetes is an example of a chronic inflammatory disease (Pacher et al., 2007).

The production of ROS is a typical response to the stimulation of immune system cells (Meier et al., 1989, 1990). Both, acute and chronic inflammatory states have redox equilibrium alterations due to the increased generation of oxidizing agents (Pacher et al., 2007; Roberts et al., 2010; Li et al., 2013; Rochette et al., 2013). Toll-like receptors (TLRs) activate NFκB, a regulator of inflammation that is controlled by hundreds of genes and is also a redox-sensitive nuclear factor, are at a key juncture between the regulation of oxidative stress and inflammation.

Different experimental models from studies have described that the activation of NFκB and proinflammatory cytokines is associated to neuronal dysfunction, neuronal loss and impaired cognitive function (Mattson and Camandola, 2001; Vincent et al., 2002; Cai and Liu, 2012; Li et al., 2013). Activated NFκB can lead to oxidative stress-induced cell dysfunction or death due to the induction of cytotoxic products, which exacerbate inflammation and promote apoptosis (Pahl, 1999; Morgan and Liu, 2011).

Overnutrition is considered as an independent environmental factor which activates the innate immune system and triggers an atypical form of inflammation leading to metabolic dysfunction in the CNS (Cai and Liu, 2012). This inflammatory cascade can also affect the hypothalamus and impair appetite control, energy expenditure, carbohydrate and lipid metabolism, and blood pressure homeostasis (Kahn and Flier, 2000; Lam et al., 2005; Meister, 2007; Schenk et al., 2008; Zhang et al., 2008; Shoelson and Goldfine, 2009). The molecular pathway involved in this dysfunction is the activation of IKKβ/NFκB (Sonoda et al., 2008; Cai, 2009; Lumeng and Saltiel, 2011).

The endoplasmic reticulum (ER) also plays a key role in the metabolic imbalance caused by oxidative stress since it depends on IKKβ/NFκB pathway activity (Zhang et al., 2008; Purkayastha et al., 2011) and causes ROS accumulation (Cullinan and Diehl, 2006). Sustained exposure to high levels of blood glucose promotes oxidative stress generating oxidative free radicals and aberrant protein folding (Cullinan and Diehl, 2006).

Zhang et al. have reported an increase in the expression of C/EBP (CCAAT/enhancer-binding protein) homologous protein (CHOP) in the hippocampus of diabetic rats. This increase suggests that CHOP-ER stress-mediated apoptosis could be caused by hyperglycemia, impairing hippocampal synapses, and promoting diabetic cognitive dysfunction (Zhang et al., 2013).

**Oxidative Stress**

As previously described, IR, inflammation, and hyperglycemia all induce oxidative stress. The current concept of oxidative stress conceived by Helmut and Jones is an “imbalance between oxidants and antioxidants in favor of the oxidants, leading to a disruption of redox signaling and control, and/or molecular damage” (Sies and Jones, 2007). Free radicals are highly unstable and reactive molecules which disrupt protein structure and modify the physicochemical properties of membranes resulting in organelles and cell damage. Some cardinal examples of free radicals are the well-known ROS, which are byproducts of the partial reduction of O₂ (Figure 1). This fundamental reaction occurs in Complex IV of the ETC during physiological respiration (Mitchell, 2012).

It is known that the appearance of oxygen in our world’s atmosphere is directly correlated with the origin of the powerhouse organelles in cells: the mitochondria (Poderoso, 2016). The mitochondria not only supply the cell with a greater amount of ATP compared with other metabolic pathways but also play important roles in signaling apoptosis, thermoregulation, and other vital processes. The adaptation to an aerobic lifestyle benefited eukaryotic cells in many ways but also brought complications. Unfortunately, the aerobic environment generates ROS (Mitchell, 2012), and mitochondria are the main cellular source of ROS. Metabolically active tissues as the liver, heart, and brain are the major contributors of ROS to the body (Boveris and Repetto, 2016).

The amount of ROS, normally produced in low concentrations as byproducts of physiological processes like respiration, is regulated by a variety of enzymes and other molecules with antioxidant properties (Glutathione Peroxidase, Glutathione Reductase, SOD, Vitamin C, Vitamin E, and the β-carotenes) (Birben et al., 2012). When the redox homeostasis is affected, ROS are overproduced exceeding the physiological antioxidant capacity resulting in oxidative stress and causing structural and conformational changes in mitochondrial proteins, lipids, and nuclear material, thereby impairing their function. Mitochondrial dysfunction in particular, eventually leads to nerve cell damage. Since the nervous tissue is highly metabolically active and critically dependent on energy supply, it is unable to work properly in ATP shortcoming conditions (Bhat et al., 2015).

In diabetic patients, aging may be associated with brain dysfunction supported by the link between aging with cell death and oxidative stress mediated by free radicals (Beckman and Ames, 1998). In these pathological conditions, cellular stress triggers oxidative mitochondrial damage, which in turn may lead to apoptosis and/or necrosis (Merad-Boudia et al., 1998). Apoptosis-induced oxidative stress has been
linked to neurogenesis inhibition (Cui et al., 2006). Alteration in mitochondrial the ETC, ROS formation, dysfunction of mitochondrial metabolism, and oxidative stress are recognized as the main protagonists in complications related to diabetes (Moreira et al., 2009).

Likewise, many studies have revealed that homocysteine, associated with endothelial dysfunction, is responsible for the release of hydrogen peroxide which causes cellular oxidative stress and inflammation mediated by cell injury in vitro (Rozyczka et al., 2013). There is consensus that the activated microglia is an important key mediator of proinflammatory and neurotoxic factors involved in the progression of PD and AD. These proinflammatory and neurotoxic factors include cytokines like interleukin-6 (IL-6) and interleukin-1β (IL-1β), the tumor necrosis factor-α (TNF-α) and ROS, consequently contributing to oxidative stress (Bayarsaikhan et al., 2015).

Inexorably, altered metabolic homeostasis affecting multiple metabolic pathways in MetS becomes the driving force toward oxidative stress. The MetS should be regarded not only as a predictor of CVD and DM2 but also as a silent threat to cognitive performance and a risk for neurodegeneration (Kim and Feldman, 2015). Timely assessment of risk for MetS and its related conditions may be recommended.

Hypoxia

Metabolic syndrome (MetS) is associated with an increased risk of cerebrovascular diseases, including cerebral ischemia (Aoqui et al., 2014). The abnormal metabolic pathways involved in MetS affect a broad variety of tissues, organs and systems, including the cardiovascular system. Microvascular dysfunction is particularly associated with MetS (Czernichow et al., 2010). This is not surprising since DM2 progresses toward micro and macrovascular dysfunction (Mitchell, 2012). Furthermore, high blood pressure, increased pulse wave velocity suggesting increased arterial stiffness, and low capillary density were found in individuals with MetS (Greenstein et al., 2009). Vascular degeneration brings forth a flawed circulation, which in turn leads to hypoxia in target organs like the brain.

There is ever-growing evidence for obesity associated with changes in perivascular adipose tissue, which gives forth an altered vasoactive tone of the microvasculature (Obadia et al., 2017). Some key factors that may play a crucial role regarding these vascular modifications are cardiac molecules that are increased substantially in MetS: free fatty acids and adipokines (TNF-α) (Greenstein et al., 2009). Additionally, not only do individuals with MetS have a higher likelihood of microvascular dysfunction, but they are also more susceptible to damage during ischemia-reperfusion events (Aoqui et al., 2014).

The cluster of these elements poses important risk factors toward producing hypoxia in tissues that have a strict oxygen supply requirement, such as nervous tissue. The neurovascular unit (composed of neurons, astrocytes and endothelial cells) is the structure in charge of maintaining the brain’s homeostasis (Gorelick et al., 2011). Studies show that the dysfunction of this unit plays a crucial role regarding the onset of neurodegenerative conditions, such as AD (Zlokovic, 2008; Grammas, 2011; Marchesi, 2014). In fact, reports have associated stroke patients with progression toward AD, where hypoxic/ischemic injury promotes the formation of β-amyloid plaque (Guglielmotto et al., 2009).

NEUROPROTECTION

Neuroprotection encompasses the therapeutic actions to prevent or limit the progression of neuronal degeneration (Orsini et al., 2016). A vast array of noxious stimuli can trigger damage in nervous tissue. Among these, altered metabolic pathways and hypoxia are the main focus of this review (Marcano Torres, 2004).

The therapeutic approaches regarding neuroprotection discussed in this review comprise three instances: lifestyle habits, MetS symptoms medication (hypertension, hyperglycemia, and dyslipidemia), and antioxidant treatment.

Lifestyle: Nutritional Habits and Exercise

A fundamental cornerstone of neuroprotection in the context of MetS concerns striving toward physical wellness obtained by a balanced diet and exercise through a multidisciplinary approach. This item alone can revert hypertension, hyperglycemia, and dyslipidemia, without the need to implement medication (Pitsavos et al., 2006).

Nutritional Habits

Reducing daily calorie intake and adopting a dietary style like the Mediterranean diet or the Dietary Approaches to Stop Hypertension (DASH) is advisable. While both dietary strategies improve the patient biochemical profile, the DASH was more beneficial in normalizing blood pressure (Kaur, 2014). The Adult Treatment Panel III (ATP III) recommends a diet for cholesterol management containing 25–35% of total fat to reduce the low density-cholesterol (LDL-C) fraction level (National Cholesterol Education Program, 2001). We have reported that chronic consumption of cola beverages impairs metabolic homeostasis increasing glycermia, cholesterolemia, triglyceridemia, and systolic blood pressure. Systolic blood pressure and most of the biochemical parameters normalize after switching cola beverages to tap water over a sustained washout period. However, hypertriglyceridemia is resistant and persists long after discontinuing cola consumption (Milei et al., 2011; Otero-Losada et al., 2014, 2015, 2016a).

Exercise

Health professionals should indicate exercise programs, such as 30 min or more of moderate-intensity physical activity and preferably all days of the week (Thompson et al., 2003). Continuing evidence from our research reports a beneficial effect of exercise on pancreatic morphology in long-term cola-drinking rats. These results support the by now accepted positive correlation between exercise and physical wellness (Otero-Losada et al., 2016b).

However, when modifying lifestyle habits does not revert pathological values, it is time to take the next level of action including a pharmacological therapeutic approach. Nevertheless, physical wellness should always compliment the medication.
Medication Targeted Toward Mets Cardinal Symptoms

The cardinal symptoms of MetS with indicated pharmacological treatment are hypertension, dyslipidemia, and hyperglycemia.

Hypertension

At present, a vast array of antihypertensive drugs is available (Gupta and Gutha, 2010). However, the election of a specific pharmacological association should consider a holistic view of each patient, always bearing in mind the individual idiosyncrasy and any other relevant factor (Gutiérrez, 2001). There is a certain structure regarding the course of drug administration that is validated by clinical trials in hypertensive patients. Treatment should initiate with a mono-drug treatment and only escalate indicating additional drugs with different mechanism of action in patients that do not normalize their blood pressure (Rivas-Chávez et al., 2007).

The first line drugs in pharmacological therapy:\footnote{National Institute for Health and Clinical Excellence Hypertension (CG127). http://www.nice.org.uk/guidance/cg127. Accessed October 10, 2017.}

- Angiotensin Converting Enzyme (ACE) inhibitors/Angiotensin II Receptor Blockers (ARBs) which inhibit receptor binding to angiotensin II.
- Dihydropyridine Calcium Channel Blockers (CCBs) which inhibit Ca\(^{2+}\) influx into smooth muscle cells in vessels.
- Thiazide Diuretics which inhibit the reabsorption of Na\(^{+}\) and Cl\(^{-}\) in the distal tubules of the nephron.

The second line drugs in pharmacological therapy are administered to patients with risk factors or developing side effects from the first-line drugs (Gutiérrez, 2001; Sweitzer, 2003; De Luís Román et al., 2008).

Dyslipidemia

The pharmacological approach to normalize blood lipids comprises a variety of drugs indicated according to the patient’s specific abnormality (Tonkin and Byrnes, 2014). In patients with MetS, the pharmacological goal is to decrease the LDL-C fraction and triglycerides, and increase the HDL-C fraction in blood. The classical first-line drugs involve statins, fibrates and inhibitors of cholesterol absorption while thiazolidinediones, GLP-1 agonists, and DPP-4 inhibitors seem to be promising therapeutic alternatives (Binesh Marvasti and Adeli, 2010).

Statins decrease LDL-C level acting as inhibitors of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, which is the key enzyme in cholesterol endogenous synthesis (Baigent et al., 2010). Most frequent adverse side effects of long-term treatment with statins are hepatotoxicity and myopathy (Pescio, 2001).

Ezetimibe, the standard cholesterol absorption inhibitor, impairs cholesterol luminal transport in the small intestine by the enterocyte (Tonkin and Byrnes, 2014). This drug lowers blood level of LDL-C and its effect increases when associated with a statin (Binesh Marvasti and Adeli, 2010).

Another drugs used in MetS are the fibrates, which activate peroxisome proliferator-activated receptors (PPARs)

eventually improving lipid and carbohydrate metabolism. The fibrates are very effective at lowering blood triglycerides, reducing LDL-C, and increasing HDL-C as well (Staels et al., 1998). The thiazolidinediones are insulin-sensitizing drugs (i.e., rosiglitazone) that also act as PPARs stimulators and are used to normalize glycemia (Krentz et al., 2008).

The incretins, typically, the glucagon-like peptide-1 (GLP-1) and the glucose-dependent insulino tropic peptide (GIP), are gut hormones secreted by the enteroendocrine cells within minutes after ingestion and they stimulate insulin secretion after eating (Ahren, 2003). Their use is promising in patients with DM2 (Meier and Nauck, 2006). The dipeptidyl peptidase-4 (DPP-4) is the enzyme responsible for lowering the level of incretin in blood to the basal level. Hence, the administration of DPP-4 inhibitors increases insulinemia (Kendall et al., 2006).

Hyperglycemia

The leading non-insulin antidiabetic pharmacological groups are the insulin-sensitizing drugs (biguanides and thiazolidinediones), insulin secretagogues (sulfonylureas, meglitinides, and incretins), and starch blockers (α-glucosidase inhibitors) (Rockville, 2007; Zárate et al., 2010; Powers and D’Alessio, 2012). The preferred drugs in MetS are those that do not have a direct effect on pancreatic β-cells, such as biguanides (metformin), thiazolidinediones (rosiglitazone), and α-glucosidase inhibitors (acarbose) (Mamedov and Shishkova, 2007). The main advantage of these euglycemic agents is avoiding hypoglycemia as a side effect (Vlckova et al., 2009).

Data describing clinical evidence concerning anti-MetS treatment and its effect on cognitive impairment is summarized in Table 1.

Medication Targeting Oxidative Stress

As described in this review, the common denominator of various pathological pathways is an overall pro-oxidative status. The use of diverse antioxidative strategies has been evaluated to mitigate oxidative stress, mainly in diabetic neuropathy (Spychalowicz et al., 2012).

Antioxidant Drugs

Among the wide variety of antioxidant compounds, the following have been thoroughly studied:

- Vitamins A, C, and E
- Flavonoids
- Alpha-lipoic acid (ALA)
- Lutein and docosahexaenoic acid (DHA)

Other antioxidants have shown neuroprotection as well. Such is the case of the amino acids Taurine, acetyl L-carnitine, N-acetylcysteine (Negre-Salvayre et al., 2008; Shakher and Stevens, 2011; Wang et al., 2011; Hosseini and Abdollahi, 2013), synthetic ROS scavengers like tempol and SOD mimetics (De Silva and Miller, 2016), and resveratrol which decreases the activity of NF-κB. Also, TNF-α, IL-6, and Cox-2, angiopoietin-1 which protects against brain stroke (Nguyen et al., 2012), the anti-inflammatory cytokines IL-10 and IL-8 (Shukla et al., 2017), mitochondrial antioxidants as the coenzyme Q10 (Chew and
TABLE 1 | Effect of anti-MetS treatment on cognitive processes, and brain circulation and metabolism in clinical trials.

| Symptoms          | Drug                        | n    | Sample Characteristics               | Study Time       | Results                                                                 | References           |
|-------------------|-----------------------------|------|--------------------------------------|------------------|--------------------------------------------------------------------------|----------------------|
| HYPERTENSION      | ACE inhibitor               | 616  | Mild/Moderate AD                     | 4-year prospective | Mini-Mental State Examination (MMSE) decline between control and placebo  | Soto et al., 2013    |
|                   | CCB                         | 18,423 | Elderly hypertensive patients older than 60 years | 12-year prospective | CCB use significantly reduced the risk of total dementia, Alzheimer’s dementia, and vascular dementia | Hwang et al., 2016   |
|                   | Thiazide Diuretics          | 3,417 | Elderly hypertensive population with AD | 7-year prospective | Use of any anti-hypertensive medication was associated with lower incidence of AD. Thiazides were associated with the greatest reduction of AD risk | Chuang et al., 2014  |
| HYPERGLYCEMIA     | Metformin (Biguanides)      | 20   | Mild cognitive impairment or mild dementia due to AD | 16-week prospective | Metformin was associated with improved executive functioning, and trends suggested improvement in learning/memory and attention | Koenig et al., 2017  |
|                   | Pioglitazone (TZD)          | 42   | Mild AD with type II Diabetes Mellitus | 6-month prospective | The pioglitazone group improved cognition and regional cerebral blood flow in the parietal lobe | Sato et al., 2011    |
|                   | Rosiglitazone (TZD)         | 30   | Mild AD or amnestic mild cognitive impairment | 6-month prospective | Relative to the placebo, better delayed recall, and selective attention | Watson et al., 2005  |
|                   | GLP-1 agonists              | 9    | Healthy, Caucasian males with a mean age of 22 years old | 4-week prospective | Ensures less fluctuation of brain glucose levels | Gejl et al., 2012    |
| DYSLIPIDEMIA      | Simvastatin                 | 46   | 45–64 year old participants with normal cognition, grouped by high or normal cholesterol | 12-month prospective | Reduction of p-tau in CSF seen in patients who had high initial baseline LDL cholesterol | Li et al., 2017      |

ACE, angiotensin converting enzyme; CCB, calcium channel blockers; TZD, thiazolidinedione; CSF, cerebral-spinal fluid; LDL, low-density lipoprotein.

Watts, 2004), and uncoupler proteins (UCPs) (Harper et al., 2001; Green et al., 2004) have neuroprotective effects. Some of these drugs as tempol and the anti-inflammatory cytokines have improved the response to hypoxic events reducing the spread of microhemorrhages (Han et al., 2015; Shukla et al., 2017).

Vitamins A, C, and E are dietary antioxidants capable of directly reducing free radicals and participating in the recycling of antioxidant cofactors (Maritim et al., 2003). The antioxidant vitamins also boost the immune system, preserve DNA structure avoiding oxidative damage, and alleviate diabetic neuropathy symptomatology, all linked with oxidative stress reduction (Niedowicz and Daleke, 2005; Rahman et al., 2006; Valko et al., 2007; Salah et al., 2010).

Several subclasses of flavonoids are free radical scavengers found in plants (Njiveldt et al., 2001; Arts and Hollman, 2005; Nettleton et al., 2006; Lukačínová et al., 2008). Some examples are: proanthocyanidin, luteolin, hesperidin, fisetin, epigallocatechin-gallate, rutin, and quercetin have been shown to possess antioxidant activities which protect against diabetic neuropathy (Al-Enazi, 2003; Cui et al., 2008; Ibrahim, 2008; Maher et al., 2011; Wang et al., 2011; Baluchnejadmojarad and Roghani, 2012; Ferreira et al., 2013).

Alpha-lipoic acid (ALA), an amphiphile antioxidant molecule, has proved to be likely the most successful antioxidant in clinical trials (Vallianou et al., 2009). Both ALA and its active metabolite (DHLA), act at different levels as antioxidants; they are free radical scavengers, inhibit the hexosamine and AGEs pathways, and are also involved in the intracellular regeneration of ascorbic acid (vitamin C), alpha-tocopherol (vitamin E), and oxidized glutathione (GSSG) (Packer et al., 2001; Du et al., 2008; Vallianou et al., 2009). Many experimental models support the beneficial effects of ALA in diabetic neuropathy (Nagamatsu et al., 1995; Evans et al., 2002; Ametov et al., 2003; Baydas et al., 2004; Ziegler et al., 2004, 2006, 2011; Tankova et al., 2005; Du et al., 2008; Huang and Gitelman, 2008; Gianturco et al., 2009; Vallianou et al., 2009).

The advantageous treatment with lutein and DHA in the brain of diabetic animals, and the way that these substances were able to mitigate the intrinsically oxidative environment in diabetes has also been studied (Muriach et al., 2006; Arnal et al., 2010). Moreover, treatment with DHA improved memory and learning skills in patients with Alzheimer’s disease, related to a decrease in the concentration of lipid peroxide and ROS (Hashimoto et al., 2005).
Mitigating Oxidative Stress Pathways

Diverse research projects have studied the downstream sequence of reactions and biochemical avenues undergoing oxidative stress as possible targets for the treatment of oxidative neuropathy. For the purpose of this review, we will focus on Aldose Reductase Inhibitors (ARIs), PKC Inhibitors, and Anti-AGE Agents.

Aldose Reductase Inhibitors (ARIs)
The aldose reductase enzyme participates in the synthesis of sorbitol and fructose. The ARIs decrease the amount of glucose entered into the polyol pathway avoiding neuronal accumulation of sorbitol and fructose. Based on the positive effect of ARIs administration in neuropathies caused by oxidative stress (Hotta et al., 1996; Yagihashi et al., 2001), clinical trials were conducted to test the effects of Fidarestat (SNK-860) (Hotta et al., 2001), Epalrestat (Hotta et al., 2006; Ramirez and Borja, 2008; Sharma and Sharma, 2008), and Ranirestat (AS-3201) (Bril and Buchanan, 2004; Bril et al., 2009). To date, only Epalrestat has a license in Japan while the other two were removed from the market (Casellini and Vinik, 2006; Kawai et al., 2010; Schemmel et al., 2010).

Protein Kinase C (PKC) Inhibitors
The PKC enzyme participates in the activation of key regulatory proteins for the synthesis of neurotransmitters, and it is essential for nerve impulse conduction. Different studies have shown that PKC participates in alleviating neuropathic pain (Chattopadhyay et al., 2008; Norcini et al., 2009). The specific PKC-1b inhibitor Ruboxistaurin improved axonal velocity and endoneurial blood flow in diabetic rats (Nakamura et al., 1999). In clinical trials, Ruboxistaurin slowed down the progression of diabetic neuropathy but was not effective in suppressing the neuropathic symptomatology (Vinik et al., 2005).

Anti-advanced glycation end products (AGEs) Agents
Some drugs may prevent or inhibit AGEs formation and accumulation. The anti-AGEs drug's family is also responsible for disrupting the interaction between AGEs and AGE receptors (RAGEs), which would otherwise magnify oxidative damage. Some examples of these agents are Benfotiamine, Aminoguanidine, Aspirin, and Rapamycin (Haupt et al., 2005; Edwards et al., 2008).

- Benfotiamine increases the activity of the Transketolase enzyme which is responsible for directing AGE substrates to the phosphate pentose pathway, consequently reducing hyperglycemic damage. Benfotiamine also inhibits the increase in UDP-N-acetylglucosamine (UDP-GlcNAC), which in turn limits the substrate's capacity to enter the hexosamine pathway, reducing AGEs production (Stirban et al., 2007; Balakumar et al., 2010).
- Aminoguanidine reacts with 3-deoxyglucosone, an AGE precursor, inactivating the reactive carbonyl residues essential to enzymatic activity, and preventing AGEs formation. Studies on this compound, however, have been discontinued due to its toxicity (Yan et al., 2008).
- In Vitro studies have shown that aspirin inhibits the production of pentosidine (an AGE) by accepting free radicals and ionic chelants in the presence of collagen (Urios et al., 2007).
- Ding et al. studied the activity of Rapamycin, an inhibitor of the proapoptotic mTOR-p53-Bax pathway, showing that Rapamycin injection 4 h after causing an injury, improved functional recovery. Recovery consisted of a reduction in microglial and macrophage activation, a decreased rate of apoptosis, and an improved neurobehavioral function (Ding et al., 2015).

Our Research
As already mentioned, one of our research lines investigates the effects of chronic cola beverages consumption in murine models. Clear evidence of beneficial effects of a wash-out period (diet) and exercise have been reported (Milei et al., 2011; Otero-Losada et al., 2014, 2015, 2016a,b).

Another study conducted in our institution included elderly patients of both sexes that attended periodical routine check-ups, with the purpose of evaluating the effectiveness of short-term antioxidant supplementation. The outcome of our study confirmed that antioxidant supplementation improved plasma biochemistry as a result of changes in oxidative metabolism, typically in those patients having low basal endogenous antioxidants concentration in plasma. Based on these results, we recommended measuring the basal level of plasma antioxidants before starting any supplementation with antioxidants in elderly cardiovascular patients, a particularly vulnerable population with special precautions to be endorsed. Not only adverse effects were not reported during the course of our study, but subjective observations as “feeling more vital” or experiencing a state of “general well-being” were declared (Otero-Losada et al., 2013).

Using an experimental model, we assessed the therapeutic benefits of medical grade ozone, a mixture of 0.05–5% of pure O3 and 95–99.5% of pure O2 according to the pharmaceutical legislation. We reported promising effects of medical ozone auto-hemotransfusion on the cardiovascular system injury. Pretreatment with ozone auto-hemotransfusion decreased neointimal proliferation and induced reendothelialization following a metal stent insertion (Barone et al., 2016). The protective mechanism whereby ozone reduces restenosis appears to involve the ozone well-described oxidative preconditioning upregulating the antioxidant enzymes, and improving the antioxidant response to an eventual injury (Barone et al., 2016). Cognitive impairment or skills were not assessed in these experimental models. However, the promising outcome encourages pursuing further study of cognitive abilities as well.

Clinical Relevance Regarding Neurodegenerative Diseases
Among neurodegenerative disorders, AD has been extensively studied regarding cognitive impairment in the setting of MetS (Hashimoto et al., 2005; Moreira et al., 2009; Mayeux and Stern, 2012; Zhang et al., 2013; Jayaraman and Pike, 2014; Kleinridders et al., 2014; Kim and Feldman, 2015). This tendency is reasonable since there is genetic evidence showing the apolipoprotein E (ApoE) as a common gene which links dementia, MetS, and diabetes (Zhang et al., 2017). Moreover, it is also crucial to bear
The emerging global epidemic of neurodegenerative disorders as the world population ages is of great concern (Brookmeyer et al., 2007). Any insight regarding neuroprotection and delaying the onset of cognitive impairments is of utmost value. The ever-growing evidence of the association between AD and MetS not only allows a deeper comprehension of the pathogenic circuits but also lays the foundations for developing new therapeutic approaches aimed at normalizing both shared and intertwined pathological pathways underlying the two conditions (Agüero-Torres et al., 1998; Geldmacher et al., 2006; Venkatesan et al., 2017; Chen et al., 2016; Pan et al., 2016; de la Monte, 2017; Rojas-Gutierrez et al., 2017; Vieira et al., 2017; Zhang et al., 2017).

**CONCLUSION**

Metabolic Syndrome (MetS) is an ever-growing disorder affecting up to 25% of the population in industrialized countries increasing morbimortality. Given these proportions, it has become an epidemic of public health concern. Increasing evidence shows that MetS is a risk factor for neurological disorders, beyond its classical association with CVD and DM2. Hyperglycemia, IR, inflammation, oxidative stress, and hypoxia are key pathological pathways associated with MetS. It is a question of time until this cluster of conditions results in tissue damage in target organs such as the brain and the microvasculature that irrigates the nervous system. Oxidative stress and hypoxia are actually linked to neurological diseases like Alzheimer’s and Parkinson’s (Kim and Feldman, 2015).

The therapeutic strategies suggested in this review entail multidisciplinary interventions involving different pathological pathways in concert. These include improving lifestyle and daily habits (diet and exercise), treating the cardinal symptoms of MetS, and reducing the pro-oxidative load in affected patients. Antioxidant therapy is not routinely used in MetS, although extensive research relative to its benefits in diabetic neuropathy is available. Hence, we consider that diminishing the pro-oxidative status in patients with MetS may play a critical role in reducing brain hypoxic damage and behavioral deficits.

**AUTHOR CONTRIBUTIONS**

ME: Lead author; MN and BP (B.Sc.): Data collection; FB: Proofreading; JG: Laboratory research; JM: Editing; MO-L: Editing and proofreading. NL: Has interpreted the data, revised for intellectual content, approved the final version of the work to be published, and may account for a research work properly accomplished.

**ACKNOWLEDGMENTS**

This work was supported by PIP 11220150100319 from the National Research Council Argentina, CONICET granted to Matilde OTERO-LOSADA.

---

**REFERENCES**

Agüero-Torres, H., Fratiglioni, L., Guo, Z., Viitanen, M., von Strauss, E., and Winblad, B. (1998). Dementia is the major cause of functional dependence in the elderly: 3-year follow-up data from a population-based study. *Am. J. Public Health* 88, 1452–1456. doi: 10.2105/AJPH.88.10.1452

Ahrén, B. (2003). Gut peptides and type 2 diabetes mellitus treatment. *Curr. Diab. Rep.* 3, 365–372. doi: 10.1007/s11892-003-0079-9

Al-Enazi, M. M. (2003). Ameliorative potential of rutin on streptozotocin-induced neuropathic pain in rat. *Afr. J. Pharm. Pharmacol.* 7, 2743–2754. doi: 10.5897/AJPP2012.1534

Alvarez-Nölting, R., Arnal, E., Barcia, J. M., Miranda, M., and Romero, F. J. (2012). Protection by DHA of early hippocampal changes in diabetes: possible role of CREB and NF-kB. *Neurochem. Res.* 37, 105–115. doi: 10.1007/s11064-011-0588-x

Ametov, A. S., Barinov, A., Dyck, P. J., Hermann, R., Kozlova, N., Litchy, W. J., et al. (2003). The sensory symptoms of diabetic polyneuropathy are improved with α-lipoic acid: The Sydney trial. *Diabetes Care* 26, 770–776. doi: 10.2337/diacare.26.3.770

Aocci, C., Chmielowski, S., Scherer, E., Eissler, R., Sollinger, D., Heid, I., et al. (2014). Microvascular dysfunction in the course of metabolic syndrome induced by high-fat diet. *Cardiovasc. Diabetol.* 13:31. doi: 10.1186/1475-2840-13-31
Arnal, E., Miranda, M., Barcia, J., Bosch-Morell, F., and Romero, F. J. (2010). Lutein and docosahexaenoic acid prevent cortex lipid peroxidation in streptozotocin-induced diabetic rat cerebral cortex. Neuroscience 166, 271–278. doi: 10.1016/j.neuroscience.2009.12.028

Arts, I. C., and Hollman, P. C. (2005). Polyphenols and disease risk in epidemiologic studies. Am. J. Clin. Nutr. 81, 3178–3255. doi: 10.1093/ajcn/81.3.3175

Baigent, C., Blackwell, L., Emmerson, J., Holland, L. E., Reith, C., Bhala, N., et al. (2010). Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376, 1670–1681. doi: 10.1016/S0140-6736(10)61350-5

Balakumar, P., Rohilla, A., Krishan, P., Solairaj, P., and Thangathirupathi, A. (2012). The multifaceted therapeutic potential of benfotiamine. Pharmacol. Res. 61, 482–488. doi: 10.1016/j.phrs.2010.02.008

Blagosklonny, M. V. (2013). TOR-centric view on insulin resistance and diabetic complications: perspective for endocrinologists and gerontologists. Cell Death Dis. 4:e964 doi: 10.1038/cddis.2013.506

Blagosklonny, M. V. (2013). The multifaceted therapeutic potential of benfotiamine. Pharmacol. Res. 61, 482–488. doi: 10.1016/j.phrs.2010.02.008

Bril, V., Hirose, T., Tomioka, S., and Buchanaret, R. (2009). Ranirestat for chronic diabetic neurodegeneration: a possible implication for theranostics. World Allergy Organ. J. 4:e964 doi: 10.1038/cddis.2013.506

Browner, D. S., and Nicolae, D. L. (2002). Mitochondria are the main cellular source of oxygen, hydrogen peroxide, and nitrogen dioxide and a major source of reactive nitrogen species. Physiopathology and Clinical Aspects, Vol. 16, eds R. J. Gelpi, A. Boveris, and J. de la Monte, S. M. (New York, NY: Springer International Publishing), 23–36.

Brunso, H. A., López Costa, J. J., and Loidl, C. F. (eds.). (2014). “Tejido nervioso,” in Histología Médico-Práctica, Vol. 1 (Amsterdam: Elsevier), 115–131.

Cai, D., and Liu, T. (2012). Inflammatory cause of metabolic syndrome via brain stress and NF-κB. Aging 2, 98–115. doi: 10.18632/aging.100431

Casellini, C. M., and Vinik, A. I. (2006). Recent advances in the treatment of diabetic neuropathy. Curr. Opin. Endocrinol. Diabetes 13, 147–153. doi: 10.1097/01.med.0000216963.51751.7e

Chattopadhayay, M., Mata, M., and Fink, D. J. (2008). Continuous 5-iodopentose receptor activation reduces neuronal voltage-gated sodium channel (NaV1.7) levels through activation of protein kinase C in painful diabetic neuropathy. J. Neurosci. 28, 6652–6658. doi: 10.1523/JNEUROSCI.5530-07.2008

Chen, Y., Zhang, J., Zhang, B., and Gong, C. X. (2016). Targeting insulin signaling for the treatment of Alzheimer’s disease. Curr. Top. Med. Chem. 16, 485–492. doi: 10.2174/15680266156810813142423

Cheng, Z., Tseng, Y., and White, M. F. (2010). Insulin signaling meets mitochondria in metabolism. Trends Endocrinol. Metab. 21, 589–598. doi: 10.1016/j.tem.2010.06.005

Chew, G. T., and Watts, G. F. (2004). Coenzymes Q10 and diabetes mellitus: oxidative stress and the ‘re coupling hypothesis.’ QJM 97, 537–548. doi: 10.1093/qjmed/ich089

Chuang, Y. F., Breitner, J. C. S., Chiu, Y. L., Khachaturian, A., Hayden, K., Corcoran, C., et al. (2014). Cache County Investigators. Use of diuretics is associated with reduced risk of Alzheimer’s disease: the Cache County Study. Neurobiol. Aging 35, 2429–2435. doi: 10.1016/j.neurobiolaging.2014.05.002

Cui, X. P., Li, B. Y., Gao, H. Q., Wei, N., Wang, W. L., and Lu, M. (2008). Effects of grape seed proanthocyanidin extracts on peripheral nerves in streptozotocin-induced diabetic rats. J. Nutr. Sci. Vitam. 54, 321–328. doi: 10.1177/jnsv.54.321

Cui, X., Zuo, P., Zhang, Q., Li, X., Hu, Y., Long, J., et al. (2006). Chronic systemic D-galactose exposure induces memory loss, neurodegeneration, and oxidative damage in mice: protective effects of R-alpha-lipoic acid. J. Neurosci. Res. 84, 647–654. doi: 10.1002/jnr.20899

Cullinan, S. B., and Diehl, J. A. (2006). Coordination of ER and oxidative stress signalling: the PERK/NR2F signalling pathway. Int. J. Biochem. Cell Biol. 38, 317–332. doi: 10.1016/j.biocel.2005.09.018

Czernichow, S., Greenfield, J. R., Galan, P., Jellouli, F., Safar, M. E., Blacher, J., et al. (2010). Macrovascular and microvascular dysfunction in the metabolic syndrome. Hypertens Res. 33, 293–297. doi: 10.1038/hr.2009.228

de la Monte, S. M. (2017). Insulin resistance and neurodegeneration: progress towards the development of new therapeutics for Alzheimer’s disease. Drugs 77, 47–65. doi: 10.1007/s40265-016-0674-0

De Luis Román, D., Allerb, R., and Bustamante, J. (2008). Aspectos terapéuticos de la dieta en la hipertensión arterial. NefroPlus 5, 9–19.

Ding, K., Wang, H., Wu, Y., Zhang, L., Xu, J., Li, T., et al. (2015). Rapamycin alleviates streptozotocin-induced diabetic neuropathic hyperalgesia in rat: involvement of oxidative stress. Iran. J. Pharm. Res. 14, 281–292.

Ding, K., Wang, H., Wu, Y., Zhang, L., Xu, J., Li, T., et al. (2015). Rapamycin alleviates streptozotocin-induced diabetic neuropathic hyperalgesia in rat: involvement of oxidative stress. Iran. J. Pharm. Res. 14, 281–292.

Dorn, G. W., and Xie, Q. (2004). The PERK/Nrf2 signaling pathway. J. Neurosci. Res. 78, 186–191. doi: 10.1002/jnr.2004381
Ferreira, P. E. B., Lopes, C. R. P., Alves, A. M. P., Alves, E. P., Linden, D. R., Linden, D. R., et al. (2013). Diabetic neuropathy: an evaluation of the use of quercetin in the cecum of rats. *World J. Gastroenterol.* 19, 6416–6426. doi: 10.3778/j.1007-9327.6416

Fisher-Wellman, K. H., and Neufer, P. D. (2012). Linking mitochondrial bioenergetics to insulin resistance via redox biology. *Trends Endocrinol. Metab.* 23, 142–153. doi: 10.1016/j.tem.2011.12.008

Gejl, M., Egelford, L., Lerche, S., Vang, K., Böbb, M. B., Holst, J. J., et al. (2012). Glucagon-like peptide-1 decreases intracerebral glucose content by activating hexokinase and changing glucose clearance during hyperglycemia. *J. Cereb. Blood Flow Metab.* 32, 2146–2152. doi: 10.1038/jcbfm.2012.118

Geldmacher, D. S., Frolich, L., Doody, R. S., Erkinjuntti, T., Vellas, B., Jones, R. W., et al. (2012). *Nat. Immunol.*

Green, K., Brand, M. D., and Murphy, M. P. (2004). Prevention of mitochondrial hexokinase and changing glucose clearance during hyperglycemia. *Diabetes* 53, S110–S118. doi: 10.2337/diabetes.53.2007.S110

Greenstein, A. S., Khavandi, K., Withers, S. B., Sonoyama, K., Clancy, O., Jeziorska, M., et al. (2009). Local inflammation and hyphoxia abolish the protective anticontractile properties of perivascular fat in obese patients. *Circulation* 119, 1661–1670. doi: 10.1161/CIRCULATIONAHA.108.221181

Grillo, C. A., Piroli, G. G., Rosell, D. R., Hoskin, E. K., McEwen, B. S., and Reagan, L. P. (2003). Region-specific increases in oxidative stress and superoxide dismutase in the hippocampus of diabetic rats subjected to stress. *Neuroscience* 121, 133–140. doi: 10.1016/S0306-4522(03)00343-9

Guglielmotto, M., Aragno, M., Autelli, R., Gliberto, L., Novo, E., Colombatto, S., et al. (2009). The up-regulation of BACE1 mediated by hyphoxia and ischemic injury: role of oxidative stress and HIF1alpha. *J. Neurochem.* 108, 1045–1056. doi: 10.1111/j.1471-4159.2008.05858.x

Gupta, R., and Gupta, S. (2010). Strategies for initial management of hypertension. *Indian J. Med. Res.* 132, 531–542.

Gutiérrez, J. (2001). *Tratamiento de la Hipertensión Arterial*. Cambio de estilo de Vida.

Han, B. H., Zhou, M. L., Johnson, A. W., Singh, L., Liao, F., Vellimana, A. K., et al. (2015). Contribution of reactive oxygen species to cerebral amyloid angiopathy, vasomotor dysfunction, and microhemorrhage in aged Tg2576 mice. *Proc. Natl. Acad. Sci. U.S.A.* 112, E881–E890. doi: 10.1073/pnas.1414391112

Harper, J. A., Dickinson, K., and Brand, M. D. (2001). Mitochondrial uncoupling as a target for drug development for the treatment of obesity. *Obesity Rev.* 2, 255–265.

Hashimoto, M., Tanabe, Y., Fuji, Y., Kikuta, T., Shibata, H., and Shido, O. (2005). Chronic administration of docosahexaenoic acid ameliorates the impairment of spatial cognition learning ability in amyloid β-infused rats. *J. Nutr. 135, 549–555. doi: 10.1093/jn/135.3.549

Haupt, E., Ledermann, T., and Köpcke, W. (2005). Benfotiamine in the treatment of diabetic neuropathy—a three-week randomized, controlled pilot study (REDIP study). *Int. J. Clin. Pharmacol. Ther.* 43, 71–77. doi: 10.5414/CP43071 Hosseini, A., and Abdollahi, M. (2013). Diabetic neuropathy and oxidative stress: therapeutic perspectives. *Oxidat. Med. Cell. Long.* 2013:168039. doi: 10.1155/2013/168039

Hotta, N., Akamum, Y., Kawamori, R., Matsuoka, K., Oka, Y., Shichiri, M., et al. (2006). Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative aldose reductase inhibitor-diabetes complications trial. *Diabetes Care* 29, 1538–1544. doi: 10.2337/dc05-2270

Hotta, N., Sakamoto, N., Shigeta, Y., Kikka, R., and Goto, Y. (1996). Clinical investigation of epalrestat, aldose reductase inhibitor, on diabetic neuropathy in Japan: a multicenter study. *J. Diabetes Complicat.* 10, 168–172. doi: 10.1056/8727/9600113-4

Huang, E. A., and Gitelman, S. E. (2008). The effect of oral alpha-lipoic acid on oxidative stress in adolescents with type 1 diabetes mellitus. *Pediatr. Diabetes* 9, 69–73. doi: 10.1111/j.1399-5494.2007.00342.x

Kim, B., and Feldman, E. L. (2015). Insulin resistance as a key link for the increased risk of cognitive impairment in the metabolic syndrome. *Cardiol. Res. Pract.* 2014:943162. doi: 10.1155/2014/943162

Koening, A. M., Mechanic-Hamilton, D., Xie, X. S., Combs, M. F., Cappola, A. R., Xie, L., et al. (2017). Effects of the insulin sensitizer metformin in Alzheimer Disease: pilot data from a randomized Placebo-controlled Crossover Study. *Alzheimer Dis. Assoc. Disord.* 31, 107–113. doi: 10.1097/WAD.0000000000000202

Kong, C. M., Lee, X. W., and Wang, X. (2013). Telomere shortening in human diseases. *FEBS J.* 280, 3180–3193. doi: 10.1111/febs.12326
Tankova, T., Cherninkova, S., and Koev, D. (2005). Treatment for diabetic mononeuropathy with α-lipoic acid. *Int. J. Clin. Pract.* 59, 645–650. doi: 10.1111/j.1742-1241.2005.00452.x

Thompson, P. D., Buchner, D., Pita, I. L., Balad, Y. G. J., Williams, M. A., Marcus, R. H., et al. (2003). Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease. *Circulation* 107, 3109–3116. doi: 10.1161/01.CIR.0000075572.40158.77

Tonkin, A., and Byrnes, A. (2014). Treatment of dyslipidemia. *F1000 Prime Rep.* 6:17. doi: 10.12703/P-6-17

Ulusu, N. N., Sahilli, M., Avci, A., Canbolat, O., Ozansoy, G., Ari, N., et al. (2003). Pentose phosphate pathway, glutathione-dependent enzymes and antioxidant defense during oxidative stress in diabetic rodent brain and peripheral organs: effects of stobadine and vitamin E. *Neurochem. Res.* 28, 815–823. doi: 10.1023/A:102320605255

Urios, P., Grigorova-Borsos, A. M., and Sternberg, M. (2007). Aspirin inhibits the formation of pentosidine, a cross-linking advanced glycation end product, in collagen. *Diabetes Res. Clin. Pract.* 77, 337–340. doi: 10.1016/j.diabres.2006.12.024

Valko, M., Leibfritz, D., Moncol, J., Cronin, M. T., Mazur, M., and Telsar, J. (2007). Free radicals and antioxidants in normal physiological functions and human disease. *Int. J. Biochem. Cell Biol.* 39, 44–84. doi: 10.1016/j.biocel.2006.07.001

Vallianou, N., Evangelopoulos, A., and Koutalas, P. (2009). Alpha-lipoic acid and diabetic neuropathy. *Rev. Diabetic Stud.* 6, 230–236. doi: 10.1900/RDS.2009.6.230

Venkatasesan, R., Ji, E., and Kim, S. Y. (2015). Phytochemicals that regulate neurodegenerative disease by targeting neurotrophins: a comprehensive review. *Biomed Res. Int.* 2015:814068. doi: 10.1155/2015/814068

Vieira, M. N. N., Lima-Filho, R. A. S., and De Felice, F. G. (2017). Connecting Alzheimer’s disease to diabetes: underlying mechanisms and potential therapeutic targets. *Neuropharmacology* doi: 10.1016/j.neuropharm.2017.11.014. [Epub ahead of print].

Vincent, A. M., Brownlee, M., and Russell, J. W. (2002). Oxidative stress and programmed cell death in diabetic neuropathy. *Ann. N. Y. Acad. Sci.* 959, 368–383. doi: 10.1111/j.1749-6632.2002.tb02108.x

Vinik, A. I., Bril, V., Kempler, P., Litchy, W. J., Tesfaye, S., Price, K. L., et al. (2005). Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C β-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trial. *Clin. Ther.* 27, 1164–1180. doi: 10.1016/j.clinthera.2005.08.001

Vickova, V., Cornelius, V., Kasliwal, R., Wilton, L., and Shaker, S. A. (2009). Hypoglycemia with oral antidiabetic drugs: results from prescription-event monitoring cohorts of rosiglitazone, pioglitazone, metformin and repaglinide. *Drug Saf.* 32, 409–418. doi: 10.2165/00002018-200932050-00004

Wang, G. G., Lu, X. H., Li, W., Zhao, X., and Zhang, C. (2011). Protective effects of luteolin on diabetic nephropathy in STZ-induced diabetic rats. *Evid. Based Comp. Alternat. Med.* 2011:323171. doi: 10.1155/2011/323171

Watson, G. S., Cholerton, B. A., Reger, M. A., Baker, L. D., Pymate, S. R., Asthana, S., et al. (2005). Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. *Am. J. Geriatr. Psychiatry* 13, 950–958. doi: 10.1176/appi.a13.11.950

Zlokovic, B. V. (2008). New therapeutic targets in the neurovascular disease of Alzheimer’s disease and amnestic mild cognitive impairment during treatment with rosiglitazone. *Am. J. Geriatr. Psychiatry* 13, 950–958. doi: 10.1176/appi.a13.11.950

Xu, Q. G., Li, X. Q., Kotecha, S. A., Cheng, C., Sun, H. S., and Zochodne, D. W. (2004). Insulin as an *in vivo* growth factor. *Exp. Neurol.* 188, 43–51. doi: 10.1016/j.expneurol.2004.03.008

Yagishashi, S., Yamagishi, S. I., Wada, R. I., Baba, M., Hohman, T. C., Yabe-Nishimura, C., et al. (2001). Neuropathy in diabetic mice overexpressing human aldose reductase and effects of aldose reductase inhibitor. *Brain* 124, 2448–2458. doi: 10.1093/brain/124.12.2448

Yan, H., Guo, Y., Zhang, J., Ding, Z., Ha, W., and Harding, J. I. (2008). Effect of carnosine, amino guanidine, and aspirin drops on the prevention of cataracts in diabetic rats. *Mol. Vis.* 14, 2282–2291.

Zarate, A., Basurto, L., Saucedo, R., and Hernandez-Valencia, M. (2010). Guía para seleccionar el tratamiento farmacológico en diabetes 2. *Rev. Med. Inst. Mex. Seguro Soc.* 48, 293–296.

Zhang, W., Xin, L., and Lu, Y. (2017). Integrative analysis to identify common genetic markers of metabolic syndrome, dementia, and diabetes. *Med. Sci. Monit.* 23, 5885–5891. doi: 10.12659/MS.905521

Zhang, X., Xu, L., and He, D. (2013). Endoplasmic reticulum stress-mediated hippocampal neuron apoptosis involved in diabetic cognitive impairment. *Biomed Res. Int.* 2013:924327. doi: 10.1155/2013/924327

Zhang, X., Zhang, G., Zhang, H., Karin, M., Bai, H., and Cai, D. (2008). Hypothalamic IKKbeta/NF-kappaB and ER stress link overnutrition to energy imbalance and obesity. *Cell* 135, 61–73. doi: 10.1016/j.cell.2008.07.043

Zhang, W. Q., and Alkon, D. L. (2001). Role of insulin and insulin receptor in learning and memory. *Mol. Cell. Endocrinol.* 177, 125–134. doi: 10.1016/S0303-7207(01)00455-5

Ziegler, D., Ametov, A., Barinov, A., Dyck, P. J., Gurieva, I., Low, P. A., et al. (2006). Oral treatment with α-lipoic acid improves symptomatic diabetic polyneuropathy. *Diabetes Care* 29, 2365–2370. doi: 10.2337/dc06-1216

Ziegler, D., Low, P. A., Litchy, W. J., Boulton, A. J., Vinik, A. I., Freeman, R., et al. (2011). Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. *Diabetes Care* 34, 2054–2060. doi: 10.2337/dc11-0503

Ziegler, D., Sohr, C. G. H., and Nourooz-Zadeh, J. (2004). Oxidative stress and antioxidant defense in relation to the severity of diabetic polyneuropathy and cardiovascular autonomic neuropathy. *Diabetes Care* 27, 2178–2183. doi: 10.2337/diabetes.27.9.2178

Zlokovic, B. V. (2008). New therapeutic targets in the neurovascular pathway in Alzheimer’s disease. *Neurotherapeutics* 5, 409–414. doi: 10.1016/j.nurt.2008.05.011

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Etchegoyen, Nobile, Baez, Posesoski, González, Lugo, Milei and Otero-Losada. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.